P14. Abstract Title: Modulating Fibrinolysis using siRNA against Coagulation Factor XIII

High specificity, easy reversibility, and a half-life on the order of weeks; these are all major advantages that gene therapy has over traditional anticoagulants, add to that a strategy that weakens clots rather than preventing clotting altogether and prophylaxis of thrombosis may become much safer. Currently, anticoagulant drugs are used as a preventative measure for people susceptible to developing disease causing thrombi (which manifest as heart attacks, strokes, and pulmonary embolism), but they require frequent administration and their strict inhibition of clotting increases the risk of uncontrolled bleeding.

Source: Thrombosis Research - September 30, 2019 Category: Hematology Authors: A. Strilchuk, E. Conway, E. Pryzdial, P. Cullis, C. Kastrup Source Type: research